BioCentury | Oct 24, 2016
Strategy

Lilly’s history lesson

  Eli Lilly and Co. President and CEO-in-waiting David Ricks will inherit a well-stocked pipeline, seven drugs less than three years old and a much-improved growth trajectory. To maintain momentum, he’ll have to execute on...
BioCentury | Nov 3, 2014
Finance

Shooting F-stars

F-star Alpha Ltd. 's deal with Bristol-Myers Squibb Co. (NYSE:BMY) last week is the first validation of the parent platform company's strategy of speeding returns by packaging assets into corporations for buyer convenience and seller...
BC Week In Review | Aug 18, 2014
Clinical News

Efient prasugrel regulatory update

The U.K.’s NICE published final guidance recommending the use of Efient prasugrel from Eli Lilly in combination with aspirin to prevent atherothrombotic events in adults with acute coronary syndrome (ACS) or ST-segment elevation myocardial infarction...
BioCentury | Aug 4, 2014
Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
BC Week In Review | Jun 30, 2014
Clinical News

Efient prasugrel regulatory update

The U.K.’s NICE issued updated draft guidance recommending the use of Efient prasugrel from Eli Lilly in combination with aspirin to prevent atherothrombotic events in adults with acute coronary syndrome (ACS) or ST-segment elevation myocardial...
BC Week In Review | Jun 9, 2014
Company News

Daiichi Sankyo sales and marketing update

Daiichi launched Efient prasugrel in Japan to treat patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI). The National Health Insurance (NHI) price of the 3.75 mg dose is ¥282.7 ($2.77) and ¥359.8 ($3.53)...
BC Innovations | Jun 5, 2014
Strategy

Sanford-Burnham goes fourth

Sanford-Burnham Medical Research Institute 's outreach to industry has resulted historically in deals focused either on a narrow range of projects or the work of individual investigators, but the institute also has been seeking broader...
BioCentury | May 19, 2014
Finance

Play it again, Celldex

Investors flocked to Celldex Therapeutics Inc. (NASDAQ:CLDX) after the company announced a cancer immunotherapy partnership with Bristol-Myers Squibb Co. (NYSE:BMY). Buysiders may be hoping the narrow nature of the BMS deal means the biotech isn't...
BC Innovations | Apr 10, 2014
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Crystal structure of purinergic receptor P2Y G protein-coupled 12 (P2RY12; P2Y12) bound to an antagonist In vitro structural studies of P2RY12 bound to an antagonist...
BioCentury | Apr 7, 2014
Finance

1Q Stock Wrap-Up: Small but mighty

Despite a correction at the end of March, all biotech market cap segments finished the first quarter in positive territory. Microcaps set the pace with a 10% gain, while large caps added 7% and were...
Items per page:
1 - 10 of 125